Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

Complete title: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E-or BRAF Ins T mutant gliomas

Research Study Number PNOC002
 
Principal Investigator Sarah Leary
 
Phase Pilot

Research Study Description

This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E mutation.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number PNOC002
 
Contact April Smith
 
Telephone 206/884-7274
 
E-mail
 

Keywords: Brain Cancer; Glioma; Pediatric Cancers, Miscellaneous; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials